ClickPET offers technical solutions for simplifying the production of disease specific biomolecule-based radiopharmaceuticals for positron emission tomography (PET) for aiding patient selection, cancer staging and disease follow-up by diagnostic imaging. The company’s technology enables the speeding-up of new radiotracer development facilitating the discovery of new diagnostic methods for personalized medicine.


    • Founding year:
R2B project started in January 2022

    • Development phase:

    • Funding stage:
Pre-seed in 2024

    • Website:

    • Contact person info:

    • Team members: